AI주식인사이트AI Stock Insight
D

에스바이오메딕스

304360KOSDAQ의약품 제조업

37.6 / 100

Reference Date: 2026-07-24

Financial Score6.5 / 40
News Sentiment19.1 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 22.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

EsbioMedix is a biotech venture company specializing in the development and production of stem cell therapeutics, leveraging its platform technology to develop innovative drugs for various diseases. Its subsidiary, Estepham, focuses on manufacturing and selling anti-aging cosmetics and medical devices, capitalizing on the growing biopharmaceutical market trends and enhancing competitive advantages through differentiated technologies and products.

Number of Employees

52people

Average Salary

42.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.234.0Point
PBR
12.85Industry Average 0.810.0Point

15.9x industry avg (risky)

ROE
-40.30Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
72.79Industry Average 12.430.0Point

5.9x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲12.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼22.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -58.4% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 17,350Won52-week high 40,45052-week low 16,800
1-month return0.0Point

1m -22.54% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0